Literature DB >> 16871277

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.

A J Barrett1, B N Savani.   

Abstract

The realization in the 1990s that allogeneic stem cell transplants (SCT) have a potentially curative graft-versus-leukemia (GVL) effect in addition to the antileukemic action of myeloablative conditioning regimens was a major stimulus for the development of reduced-intensity conditioning (RIC) regimens, aimed primarily at securing engraftment to provide the GVL effect, while minimizing regimen-related toxicity. It is now over 10 years since RIC regimens were heralded as a new direction in the field of SCT. Over the last decade much has been learned about the ways in which the conditioning regimen can be tailored to provide adequate immunosuppression, and modulated to deliver a chosen degree of antimalignant treatment. The huge literature of clinical data with RIC transplantation now permits us to more clearly define the success and limitations of the approach. This review examines the origins of RIC SCT, explores the degree to which the initial expectations and purpose of the approach have been realized, and outlines some ways forward for the field.

Entities:  

Mesh:

Year:  2006        PMID: 16871277     DOI: 10.1038/sj.leu.2404334

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  28 in total

1.  Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies.

Authors:  Wichai Chinratanalab; Nishitha Reddy; John P Greer; David Morgan; Brian Engelhardt; Adetola Kassim; Stephen J Brandt; Madan Jagasia; Stacey Goodman; Bipin N Savani
Journal:  Exp Hematol       Date:  2012-01-21       Impact factor: 3.084

2.  Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.

Authors:  J Aoki; S Seo; H Kanamori; M Tanaka; T Fukuda; M Onizuka; N Kobayashi; T Kondo; M Sawa; N Uchida; K Iwato; T Icihnohe; Y Atsuta; S Yano; A Takami
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

3.  Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.

Authors:  Michael A Spinner; Vanessa E Kennedy; John S Tamaresis; Philip W Lavori; Sally Arai; Laura J Johnston; Everett H Meyer; David B Miklos; Lori S Muffly; Robert S Negrin; Andrew R Rezvani; Judith A Shizuru; Wen-Kai Weng; Richard T Hoppe; Samuel Strober; Robert Lowsky
Journal:  Blood Adv       Date:  2019-08-27

Review 4.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 5.  Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.

Authors:  Nishitha Reddy; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

6.  I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.

Authors:  H Yamamoto; N Uchida; N Matsuno; A Kon; A Nishida; H Ota; T Ikebe; N Nakano; K Ishiwata; H Araoka; S Takagi; M Tsuji; Y Asano-Mori; G Yamamoto; K Izutsu; K Masuoka; A Wake; A Yoneyama; S Makino; S Taniguchi
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

Review 7.  The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.

Authors:  Sarah A Wall; Steven Devine; Sumithira Vasu
Journal:  Blood Rev       Date:  2017-07-15       Impact factor: 8.250

8.  Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

Authors:  Zheng Zhou; Rajneesh Nath; Jan Cerny; Hai-Lin Wang; Mei-Jie Zhang; Hisham Abdel-Azim; Vaibhav Agrawal; Gulrayz Ahmed; A Samer Al-Homsi; Mahmoud Aljurf; Hassan B Alkhateeb; Amer Assal; Ulrike Bacher; Ashish Bajel; Qaiser Bashir; Minocher Battiwalla; Vijaya Raj Bhatt; Michael Byrne; Jean-Yves Cahn; Mitchell Cairo; Hannah Choe; Edward Copelan; Corey Cutler; Moussab B Damlaj; Zachariah DeFilipp; Marcos De Lima; Miguel Angel Diaz; Nosha Farhadfar; James Foran; César O Freytes; Aaron T Gerds; Usama Gergis; Michael R Grunwald; Zartash Gul; Mehdi Hamadani; Shahrukh Hashmi; Mark Hertzberg; Gerhard C Hildebrandt; Nasheed Hossain; Yoshihiro Inamoto; Luis Isola; Tania Jain; Rammurti T Kamble; Muhammad Waqas Khan; Mohamed A Kharfan-Dabaja; Partow Kebriaei; Natasha Kekre; Nandita Khera; Hillard M Lazarus; Jane L Liesveld; Mark Litzow; Hongtao Liu; David I Marks; Rodrigo Martino; Vikram Mathews; Asmita Mishra; Hemant S Murthy; Arnon Nagler; Ryotaro Nakamura; Sunita Nathan; Taiga Nishihori; Rebecca Olin; Richard F Olsson; Neil Palmisiano; Sagar S Patel; Mrinal M Patnaik; Attaphol Pawarode; Miguel-Angel Perales; Ioannis Politikos; Uday Popat; David Rizzieri; Brenda M Sandmaier; Bipin N Savani; Sachiko Seo; Nirav N Shah; Geoffrey L Uy; David Valcárcel; Leo F Verdonck; Edmund K Waller; Youjin Wang; Daniel Weisdorf; Baldeep Wirk; Eric Wong; Jean A Yared; Wael Saber
Journal:  Blood Adv       Date:  2020-07-14

9.  Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.

Authors:  Daniel Weisdorf; Mary Eapen; Annalisa Ruggeri; Mei-Jie Zhang; Xiaobo Zhong; Claudio Brunstein; Celalettin Ustun; Vanderson Rocha; Eliane Gluckman
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-26       Impact factor: 5.742

Review 10.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.